Russia’s first potential COVID-19 vaccine will win local regulatory approval in the first half of August and be administered to frontline health workers soon afterwards, a development source close to the matter told Reuters.A state research facility in Moscow – the Gamaleya Institute – completed early human trials of the adenovirus-based vaccine this month and expects to begin large-scale trials in August.The vaccine will win regulatory approval from authorities in Russia while that large-scale trial continues, the source said, highlighting Moscow’s determination to be the first country in the world to approve a vaccine.